The DAP12-BB CAR exerts a lower toxicity profile and enhanced anti-tumor activity in B cell malignancies, given the highly adverse biological features of the enrolled subjects’ B-ALL, including high tumor burden, rapidly progressing disease, and high-risk genetics. Here, TYROBP is linked to acute lymphoblastic leukemia.